Simplified Antiviral Treatment Strategy for Hepatitis C in Ukraine

Status Completed

Clinical Trial Summary

The project will evaluate cost and treatment outcomes of a simplified Hepatitis C Virus (HCV) testing, treatment and care model integrated with HIV testing and treatment among key affected populations in Ukraine.

Clinical Trial Description

Affected populations will be screened for HCV and HIV and those HCV positive treated with direct with direct acting anti-HCV agents (DAAs), a fixed-dose combination of sofosbuvir/ledipasvir (SOF/LDV) for 12 weeks with or without weight-based ribavirin. Before and after completion of the treatment course viral load assessments will be undertaken using low-cost laboratory monitoring for comparison to standard HCV viral load measurement. Up 800 patients enrolled on treatment will be followed up at 4, 8, 12 and 24 weeks when Sustained Viral Response (SVR) will be determined. Safety monitoring will be undertaken at applicable visits for those on Ribavirin and all adverse events will be reported based on Good Clinical Practice (GCP). In addition to assessing cost outcomes, the project will assess HCV treatment efficacy in terms of SVR at 12 weeks after end of treatment ( defined as undetected HCV RNA or less than lower limit of detection), compare the cost of low cost viral assay platforms to standard of care, assess rates of ART initiation and virologic suppression of HIV-infected persons within the simplified HCV treatment model and impact of HIV co-infection in participants on the HCV treatment outcome of SVR12. The project will be conducted at 2 treatment sites in Kiev. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04038320
Study type	Observational
Source	Right to Care
Contact
Status	Completed
Phase
Start date	March 26, 2018
Completion date	June 30, 2019

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02907996` - Evaluate the Safety and Effectiveness of Sovaldi in Participants With Chronic Hepatitis C Virus (HCV) Infection in Korea
Completed	`NCT02207088` - Ombitasvir/ABT-450/Ritonavir and Dasabuvir With or Without Ribavirin in HCV Genotype 1-Infected Adults With Chronic Kidney Disease	Phase 3
Not yet recruiting	`NCT02893046` - HCV Care Pathway in Ile-de-France	N/A
Completed	`NCT01428063` - Study With PegInterferon Alfa-2a, Ribavirin and BMS-790052 With or Without BMS-650032 for Participants in Some Hepatitis C Virus (HCV) Trials	Phase 2
Completed	`NCT01396005` - A Study to Evaluate the Pharmacokinetic Effect of SCH 503034 (Boceprevir) on Methadone or Buprenorphine/Naloxone Plasma Concentrations (P08123)	Phase 1
Completed	`NCT01195181` - Different PEG-interferon and Ribavirin Schedules for Chronic Hepatitis C in the Real Clinical Practice.	Phase 4
Completed	`NCT00219999` - Hepatitis C Virus and the Humoral Immune System	N/A
Completed	`NCT02243293` - A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotypes 2, 3, 4, 5 or 6 Infection	Phase 2/Phase 3
Completed	`NCT02265237` - A Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir Co-administered With Ribavirin (RBV) in Adults With Genotype 4 Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis (AGATE-1)	Phase 3
Not yet recruiting	`NCT06104046` - Prevalence of Seroconversion of Hepatitis c Virus Among Children With CKD on Regular Hemodialysis
Completed	`NCT02604017` - A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Subjects With Genotype 1 Infection	Phase 3
Withdrawn	`NCT00947245` - Japanese Bridging Study Conducted in the United States	Phase 1
Completed	`NCT01713283` - Sofosbuvir Plus Ribavirin in Treatment-Naive and Treatment-Experienced Egyptian Adults With Chronic Genotype 4 Hepatitis C Virus (HCV) Infection	Phase 2
Completed	`NCT01479881` - A Study in Healthy Participants Investigating the Effect of TMC435 on the Pharmacokinetics of Immunosuppressants Cyclosporine and Tacrolimus	Phase 1
Completed	`NCT01458535` - A Study to Evaluate ABT-450 With Ritonavir (ABT-450/r) When Given Together With ABT-267 and With and Without Ribavirin (RBV) in Treatment-Naïve Subjects With Genotype 1, 2 or 3 Chronic Hepatitis C Virus (HCV)	Phase 2
Completed	`NCT01241773` - TMC435-TiDP16-C123 - A Study in Healthy Volunteers Investigating the Pharmacokinetic Interaction Between TMC435 and the Antiretroviral Agents Efavirenz and Raltegravir	Phase 1
Completed	`NCT01193361` - Ph IIA Study (SOC +/- NS5B)	Phase 2
Completed	`NCT01006031` - Retreatment With High Doses of pegIFN Alfa-2a and Ribavirin of Previous Nonresponders HIV-coinfected Patients With Cirrhosis Due to HCV 1-4	Phase 2/Phase 3
Completed	`NCT00819026` - Observational Trial of Hepatitis C Virus Infected Patients on Calcineurin Inhibitors	N/A
Completed	`NCT00382798` - Adaptive Phase I HCV Study With Nucleoside Analogue, in Combination With Interferon and Ribavirin	Phase 1/Phase 2